NewNo. 014
Retatrutide Pen
Synedica pre-filled pen: 40 mg retatrutide, with needles
- Size
- 40 mg pen
- HPLC
- 99.752%
- Lot
- 07022601
ALTA PEPTIDES supplies research peptides for laboratory use only. You must be at least 18 to enter.
By entering you agree these products are for research use only and not for human consumption.
Pre-filled pen: 40 mg semaglutide, GLP-1 receptor agonist
Lot certificate published at release
A sealed pre-filled pen holding 40 mg of semaglutide, the 31-amino-acid GLP-1 receptor agonist peptide. Arriving soon in UK stock; register to hear the price and release date first.
Semaglutide is a synthetic peptide, 31 amino acids long, that copies the gut hormone GLP-1. Natural GLP-1 is released after a meal, slows the stomach, reduces appetite and helps the pancreas release insulin when blood sugar is high, but it is broken down within about two minutes. The semaglutide peptide has two changes that protect it: one swapped amino acid that blocks the enzyme DPP-4, and a fatty-acid side chain that binds albumin in the blood. Together they stretch its half-life to about a week.
It was developed by Novo Nordisk and is the active ingredient in the licensed medicines Ozempic, Wegovy and Rybelsus. Our GLP-1 receptor agonists explainer tells the story from the first GLP-1 drugs to today.
In STEP 1, a 68-week trial in 1,961 adults with obesity published in the New England Journal of Medicine in 2021, average body-weight loss was 14.9% in the semaglutide 2.4 mg arm against 2.4% on placebo. In the SELECT trial of 17,604 adults with cardiovascular disease, published in 2023, semaglutide reduced major cardiovascular events by 20%. The most common side effects reported in the trials were nausea, diarrhoea, vomiting and constipation.
Semaglutide acts on one receptor (GLP-1), tirzepatide on two (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). In SURMOUNT-5, a direct 72-week comparison published in 2025, semaglutide produced 13.7% average weight loss against 20.2% for tirzepatide. Retatrutide reported 28.3% at 80 weeks in its own TRIUMPH-1 trial. Our retatrutide vs tirzepatide vs semaglutide comparison sets the trials side by side, and our article on muscle loss on GLP-1 peptides covers the body-composition data. The tirzepatide pen is also coming soon, and the retatrutide pen and retatrutide vials are in stock now.
The semaglutide pen is a sealed, pre-filled pen containing 40 mg of semaglutide in solution, filled by the manufacturer, not by ALTA PEPTIDES. A pen arrives ready-made, where a semaglutide vial is a dry powder that a laboratory reconstitutes itself. Our pen vs vial guide explains the trade-offs, which are the same for every peptide in this class. The certificate of analysis for the semaglutide in each lot will be published on this page before the pen goes on sale.
Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus, prescription-only medicines licensed in the UK. This pen is not Ozempic or Wegovy, is not made or endorsed by Novo Nordisk, and is not a medicine. It is research-grade semaglutide supplied for laboratory research only, not for human use. Anyone seeking treatment should speak to a doctor or a registered pharmacy. Our guide to UK peptide law explains the difference between licensed medicines and research compounds.
The semaglutide 40 mg pen is arriving soon in UK stock. The price, release date and lot certificate will be posted here first. Register above to be told the day it is available.
Semaglutide is a long-acting analogue of the incretin hormone glucagon-like peptide-1. The UK prescribing information for Ozempic describes it as a GLP-1 receptor agonist that binds to and activates the GLP-1 receptor. It reports that semaglutide lowers blood glucose by stimulating insulin secretion and lowering glucagon secretion when glucose is high, with a minor delay in gastric emptying after a meal. Ozempic is licensed for the treatment of adults with insufficiently controlled type 2 diabetes, and Wegovy for weight management in adults, each as a weekly subcutaneous injection. Liraglutide (Saxenda) is another GLP-1 analogue in the same pharmacological class.
Those are prescription-only medicines, made by Novo Nordisk and supplied through a prescriber or a registered pharmacy. The pen listed on this page is a different thing. It is a research item that is not in stock, it is not Wegovy or Ozempic, and it is not a licensed medicine. As a supplier, ALTA lists it for laboratory research use only, not for human consumption, and gives no guidance on human use. Our GLP-1 receptor agonists explainer covers the metabolic research behind the class.
NewNo. 014
Synedica pre-filled pen: 40 mg retatrutide, with needles
NewNo. 013
GLP-1 / GIP / glucagon triple receptor agonist